Xcelience employs “CFS1200 capsule filling and sealing machine.”
Xcelience's implementation of the CFS1200 will allow its formulation scientists the opportunity to accelerate the drug development timeframe.

March 14, 2007 (Tampa, FL) - Xcelience, LLC, has enhanced its services with the addition of the CFS1200 which allows formulation scientists the opportunity to accelerate the development timeframe. This is done by filling and sealing up to 1,200 capsules per hour with liquid or semi-solid formulations without banding.

This CFS1200 technology will benefit Xcelience’s client base by facilitating rapid development and manufacturing of multiple strengths of simple liquid-filled capsule products. Xcelience can now leverage its expertise in the development of lipid formulations for very poorly soluble drugs by accelerating the delivery of enhanced-bioavailability products for animal and clinical studies. The CFS1200 also complements Xcelience’s “Xcelodose® 600 precision micro filling system,” by accelerating the development and manufacturing of early-stage clinical supplies of drug which cannot be dosed as unformulated API. Xcelodose® is a registered trademark of Capsugel BVBA.

“The addition of the CFS1200 further supplements Xcelience’s capabilities and services for supporting early drug development,” according to Xcelience Vice President, Randall H. Guthrie. “The flexibility in providing unique services to assist companies in advancing their drug candidates into human clinical services in an efficient manner is part of our strategic plan. We will continue to provide innovative thinking to this end in order to support our clients and for the good of drug development.”